LRIG and cancer prognosis.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Accurate prognostic and predictive information is vital for optimal cancer treatment decisions.
• Leucine-rich repeats and immunoglobulin-like domains (LRIG) genes, transcripts, and proteins show potential prognostic implications across diverse cancer types.

Purpose of the Study:

• To investigate the prognostic and predictive value of LRIG genes, transcripts, and proteins in human cancers.
• To explore the role of LRIG gene expression in cancer development and patient survival.

Main Methods:

• Literature search on PubMed using keywords: lrig1, lrig2, lrig3.
• Analysis of LRIG mRNA expression in cancer versus normal tissues using the Oncomine database.

Main Results:

• LRIG1 acts as a tumor suppressor, regulating growth factor signaling.
• LRIG gene and protein expression are frequently dysregulated in human cancers, with prognostic value in breast, cervical, head-and-neck, glioma, lung, prostate, and skin cancers.
• LRIG1 and LRIG3 expression generally correlate with good survival, while LRIG2 expression is linked to poor survival; LRIG1 also influences drug sensitivity.

Conclusions:

• LRIG gene status, mRNA, and protein expression serve as clinically relevant prognostic indicators in multiple human cancers.
• LRIG analysis holds promise for informing individualized clinical decisions in cancer patient management.